Methadone

Dose and dosing duration are the dominant determinants of how long methadone remains detectable. A single low-dose exposure may clear from urine within roughly three days at the 300 ng/mL cutoff. Patients on chronic stable methadone therapy at typical OTP maintenance doses commonly remain positive for one to two weeks after the last dose because steady-state tissue stores release back into circulation slowly. The EDDP metabolite generally tracks parent methadone but may extend the window slightly because of metabolite accumulation in chronic dosing.

Route of administration matters less for methadone than for many opioids because the FDA-approved formulations are all oral (tablets, oral concentrate, dispersible tablets). Oral methadone has a high and relatively predictable bioavailability of roughly 70–80%, though inter-individual variability is substantial. Non-medical use by injection or insufflation bypasses first-pass metabolism and changes peak plasma concentration, but the long elimination half-life means the urinary detection window is not dramatically different from oral use. Magenta does not provide guidance on non-medical routes; the relevant testing-program point is that the long half-life dominates the detection profile regardless of route.

Hepatic function is critical because methadone is metabolized principally by CYP3A4 with significant contribution from CYP2B6 and lesser contributions from other cytochrome enzymes. Strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin, efavirenz, St. John's wort) can substantially accelerate methadone clearance and shorten the detection window, sometimes precipitating withdrawal in maintenance patients — this is a well-known clinical drug-interaction concern. Strong CYP3A4 inhibitors can extend clearance. CYP2B6 polymorphism is associated with inter-individual variability in methadone metabolism that affects both clinical response and detection profile. Significant hepatic impairment from cirrhosis or hepatitis prolongs clearance.

Renal function plays a smaller role for methadone than for many opioids because methadone is primarily cleared via hepatic metabolism rather than renal excretion of intact parent drug. Methadone clearance does decrease somewhat in severe renal impairment. Age, body composition, hydration status, urinary pH (methadone is a weak base and excretion increases at lower urinary pH), and concurrent medications all contribute modifying effects. Heavily dilute urine lowers analyte concentration and may produce a false negative at the cutoff; federal and most non-federal programs use creatinine and specific-gravity testing to flag dilute specimens for recollection.

Methadone is NOT included in the original SAMHSA-5 federal panel. The expanded SAMHSA Mandatory Guidelines updated in 2017 added several opioid analytes (oxycodone, oxymorphone, hydrocodone, hydromorphone) but did not add methadone as a mandatory federal analyte. Most workplace and clinical programs that include methadone do so at the industry-standard 300 ng/mL screening cutoff with a 300 ng/mL confirmation cutoff for parent methadone, with EDDP confirmation thresholds typically in the 100–300 ng/mL range depending on the laboratory.

Non-federal workplace, clinical, and OTP compliance programs commonly use the 300/300 ng/mL configuration as the de facto standard. Some specialty programs use lower cutoffs for greater sensitivity in adherence monitoring of OTP patients, where the clinical question is whether the patient is taking dispensed methadone consistently rather than whether they have used at all. Magenta's CLIA-waived methadone dip cards and the methadone analyte on our multi-panel cups are calibrated at the industry-standard 300 ng/mL cutoff by default; talk to us about custom cutoffs or about devices that include the EDDP metabolite for OTP compliance use.

Critically, the SAMHSA opiate immunoassay at 2000 ng/mL will not detect methadone. Programs that intend to monitor methadone must include a dedicated methadone-specific (MTD) assay — either as a stand-alone dip card or as part of a multi-panel device that includes methadone. For OTP compliance, panels that also test for the EDDP metabolite are increasingly preferred because EDDP presence confirms metabolized methadone use rather than recent specimen contamination with parent methadone.

Methadone urinary immunoassays use the lateral-flow competitive-binding format common to Magenta's other point-of-care devices. The test strip contains a membrane impregnated with anti-methadone antibodies and a colored conjugate. When urine wicks up the strip, free methadone from the sample competes with the labeled conjugate for antibody binding sites. If methadone is present at or above the 300 ng/mL cutoff, it occupies enough antibody binding sites that the conjugate cannot accumulate at the test line, producing a negative-line, positive-result pattern. The control line confirms reagents are working. Read time is typically five minutes.

Some immunoassays target only parent methadone; others target the EDDP metabolite specifically, and still others detect both. For OTP compliance monitoring, EDDP-targeted assays are particularly valuable because the presence of EDDP confirms that methadone was actually metabolized in vivo rather than simply added to the specimen. A specimen showing high parent methadone but no EDDP is unusual in genuine methadone users and may prompt further inquiry. Magenta's multi-panel devices that include methadone use a parent-methadone antibody by default; talk to us about EDDP-specific configurations for OTP applications.

Cross-reactivity for methadone immunoassays is generally low. Methadone has a distinctive diphenylheptanone structure unrelated to morphinan opioids, and false positives from common analgesics, antitussives, and over-the-counter medications are rare at clinical concentrations. The package insert lists the specific cross-reactive compounds the device has been tested against. Diphenhydramine, doxylamine, and certain other antihistamines have been reported in older literature as occasional sources of cross-reactivity on some methadone immunoassays, though modern devices have generally addressed this through antibody refinement. Verapamil, quetiapine, and a handful of other medications have produced isolated false positives in case reports.

Confirmation testing by gas chromatography/mass spectrometry (GC/MS) or liquid chromatography/tandem mass spectrometry (LC-MS/MS) is the gold standard for resolving any presumptive positive. These instrumental methods identify methadone and EDDP by their specific mass spectra and quantify each precisely, distinguishing methadone from any cross-reactive compound. SAMHSA-certified laboratories perform confirmation on presumptive positives, and a Medical Review Officer (MRO) reviews confirmed positives against the donor's prescription or OTP enrollment history. Valid methadone dispensed through an OTP for opioid-use-disorder treatment, or a valid prescription for analgesic methadone, is generally a legitimate medical explanation for a positive result.

Specimen validity testing should accompany every methadone screen. Creatinine, specific gravity, pH, and oxidant adulterant panels identify dilute or adulterated specimens. Because methadone is most commonly tested in OTP compliance, pain-management, and substance-use-treatment populations, sample-handling protocols should provide for repeat collection when specimens fall outside validity parameters rather than immediately classifying the result as a refusal to test. Magenta's adulteration-panel cups include integrated creatinine, pH, specific gravity, glutaraldehyde, nitrite, and oxidant test pads.